AI assistant
TREACE MEDICAL CONCEPTS, INC. — Director's Dealing 2022
Oct 22, 2022
32908_dirs_2022-10-21_f228cb0f-1363-41b1-8ca6-56c2e1841868.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK: 0001630627
Period of Report: 2022-10-19
Reporting Person: TREACE JAMES T (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-10-19 | Common Stock | S | 30397 | $22.5917 | Disposed | 1106044 | Direct |
| 2022-10-19 | Common Stock | S | 10861 | $23.3739 | Disposed | 1095183 | Direct |
| 2022-10-20 | Common Stock | S | 8742 | $23.0194 | Disposed | 1086441 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 556183 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.1600 to $23.1200 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.2600 to $24.1900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.5000 to $23.3800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.